Intra-Cellular Therapies Inc
(MEX:ITCI)
MXN
1119
0 (0%)
Market Cap: 148.50 Bil
Enterprise Value: 140.06 Bil
PE Ratio: 0
PB Ratio: 12.46
GF Score: 34/100 - Q1 2024 Intra-Cellular Therapies Inc Earnings Call TranscriptMay 07, 2024MXN1251.41Earnings
- Q4 2023 Intra-Cellular Therapies Inc Earnings Call TranscriptFeb 22, 2024MXN1020.67Earnings
- Intra-Cellular Therapies Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Intra-Cellular Therapies Inc at UBS BioPharma Conference TranscriptNov 08, 2023
- Q3 2023 Intra-Cellular Therapies Inc Earnings Call TranscriptNov 02, 2023MXN1135.67Earnings
- Intra-Cellular Therapies Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Intra-Cellular Therapies Inc at Canaccord Genuity Growth Conference TranscriptAug 09, 2023
- Q2 2023 Intra-Cellular Therapies Inc Earnings Call TranscriptAug 03, 2023MXN1135.67Earnings
- Intra-Cellular Therapies Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Intra-Cellular Therapies Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 17, 2023
- Intra-Cellular Therapies Inc at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Q1 2023 Intra-Cellular Therapies Inc Earnings Call TranscriptMay 04, 2023MXN1135.67Earnings
- Intra-Cellular Therapies Inc LUMATEPERONE Study 403 Topline Results TranscriptMar 28, 2023
- Q4 2022 Intra-Cellular Therapies Inc Earnings Call TranscriptMar 01, 2023MXN987.74Earnings
- Intra-Cellular Therapies Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Q3 2022 Intra-Cellular Therapies Inc Earnings Call TranscriptNov 03, 2022Earnings
- Q2 2022 Intra-Cellular Therapies Inc Earnings Call TranscriptAug 09, 2022Earnings
- Q1 2022 Intra-Cellular Therapies Inc Earnings Call TranscriptMay 10, 2022Earnings
- Q4 2021 Intra-Cellular Therapies Inc Earnings Call TranscriptMar 01, 2022Earnings
- Intra-Cellular Therapies Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- Q3 2021 Intra-Cellular Therapies Inc Earnings Call TranscriptNov 09, 2021Earnings
- Intra-Cellular Therapies Inc to Feature Highlights of Several of its Development Programs TranscriptOct 20, 2021
- Q2 2021 Intra-Cellular Therapies Inc Earnings Call TranscriptAug 09, 2021Earnings
- Intra-Cellular Therapies Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Intra-Cellular Therapies Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 11, 2021
- Q1 2021 Intra-Cellular Therapies Inc Earnings Call TranscriptMay 10, 2021Earnings
- Intra-Cellular Therapies Inc Investor Webcast on Lumateperone Programs TranscriptMay 04, 2021
- Q4 2020 Intra-Cellular Therapies Inc Earnings Call TranscriptFeb 25, 2021Earnings
- Intra-Cellular Therapies Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- Q3 2020 Intra-Cellular Therapies Inc Earnings Call TranscriptNov 09, 2020Earnings
- Intra-Cellular Therapies Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 16, 2020
- Intra-Cellular Therapies Inc to Discuss Positive Topline Results from Study 402 - Conference Call TranscriptSep 09, 2020
- Q2 2020 Intra-Cellular Therapies Inc Earnings Call TranscriptAug 10, 2020Earnings
- Q1 2020 Intra-Cellular Therapies Inc Earnings Call TranscriptMay 07, 2020Earnings
- Q4 2019 Intra-Cellular Therapies Inc Earnings Call TranscriptMar 02, 2020Earnings
- Intra-Cellular Therapies Inc at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Q3 2019 Intra-Cellular Therapies Inc Earnings Call TranscriptNov 05, 2019Earnings
- Intra-Cellular Therapies, Inc. - Special Call TranscriptAug 05, 2019
- Intra-Cellular Therapies Inc to Discuss the Top-line Results of Studies 401 and 404 Call TranscriptJul 08, 2019
- Q1 2019 Intra-Cellular Therapies Inc Earnings Call TranscriptMay 08, 2019Earnings
Intra-Cellular Therapies Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021 / 05:20PM GMT
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Okay. Good afternoon, everyone. Welcome to the 1:20 session here on Day 3 of the 42nd Annual Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh. I cover European and U.S. biopharmaceutical names for the firm. It's my great pleasure to be hosting Intra-Cellular Therapies today in a fireside chat session. And with that, from the company, we've got CEO, Sharon Mates; and Chief Commercialization Officer, Mark Neumann, joining us. Sharon and Mark, it's great to see you, both, welcome to the conference.
Sharon Mates
Intra-Cellular Therapies, Inc. - Co-Founder, Chairman, CEO & President
Thanks, Graig. It's a pleasure to be here.
Mark Neumann;Graig Suvannavejh
Intra-Cellular Therapies, Inc. - EVP & Chief Commercial Officer;Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Thank you, Graig.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)